Real-time Estimate
Cboe BZX
10:13:43 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
5.58
USD
|
0.00%
|
|
-12.00%
|
+28.50%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
119.7
|
89.28
|
65.58
|
46.52
|
60.03
|
-
|
-
|
Enterprise Value (EV)
1 |
119.7
|
89.28
|
65.58
|
46.52
|
60.03
|
60.03
|
60.03
|
P/E ratio
|
-14.1
x
|
-7.06
x
|
-4.61
x
|
-2.91
x
|
-2.43
x
|
-2.94
x
|
-4.24
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
30.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
30.8
x
|
EV / EBITDA
|
-
|
-7,094,197
x
|
-4,954,807
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-8,416,928
x
|
-5,125,032
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,218
|
11,188
|
10,857
|
10,869
|
10,759
|
-
|
-
|
Reference price
2 |
19.25
|
7.980
|
6.040
|
4.280
|
5.580
|
5.580
|
5.580
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
1.95
|
EBITDA
|
-
|
-12.58
|
-13.23
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.908
|
-12.59
|
-14.43
|
-17.88
|
-25.37
|
-30.74
|
-28.49
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,461.23%
|
Earnings before Tax (EBT)
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-24.8
|
-29.46
|
-27.89
|
Net income
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-24.8
|
-29.67
|
-27.89
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,430.46%
|
EPS
2 |
-1.370
|
-1.130
|
-1.310
|
-1.470
|
-2.295
|
-1.900
|
-1.315
|
Free Cash Flow
|
-
|
-10.61
|
-12.8
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-3.509
|
-4.064
|
-
|
-1.841
|
-3.493
|
-3.949
|
-4.794
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.511
|
-4.066
|
-4.395
|
-2.145
|
-3.826
|
-4.286
|
-5.19
|
-3.524
|
-4.877
|
-5.732
|
-6.196
|
-6.588
|
-7.05
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-5.441
|
-5.971
|
-6.438
|
-6.925
|
Net income
1 |
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-5.441
|
-5.971
|
-6.438
|
-6.925
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3100
|
-0.3800
|
-0.4100
|
-0.2100
|
-0.3100
|
-0.3600
|
-0.4400
|
-0.2900
|
-0.3800
|
-0.5100
|
-0.5550
|
-0.5950
|
-0.6400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/3/22
|
8/8/22
|
11/7/22
|
3/20/23
|
5/9/23
|
8/9/23
|
11/8/23
|
3/18/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-10.6
|
-12.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/21
|
3/10/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
5.58
USD Average target price
22
USD Spread / Average Target +294.27% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.50% | 60.03M | | +45.83% | 57.87B | | +40.71% | 40.25B | | -6.83% | 39.94B | | -5.16% | 28.54B | | +10.95% | 26.4B | | -20.69% | 19.33B | | +29.66% | 12.4B | | -1.39% | 12.23B | | +23.30% | 12.2B |
Other Biotechnology & Medical Research
|